UNASSIGNED: Conducted prospectively, the study enrolled 20 pre-menopausal women, aged 18 years or older, from Nanavati Max Super Speciality Hospital Mumbai, Maharashtra, India. Participants were selected based on specific inclusion criteria, including the presence of at least one uterine myoma with a minimum diameter of 2.5 cm as confirmed by ultrasound. Participants had an average age of 39.75 years and an average BMI of 27.58 kg/m2.
UNASSIGNED: The study found that mifepristone significantly reduced uterine volume by 75%, with hemoglobin levels substantially improving from 9 gm/dL initially to 12.51 gm/dL after six months. Pain intensity, assessed using the Visual Analog Scale (VAS) score, gradually decreased from baseline to three-month, with all 20 patients reporting the complete absence of pelvic pain by six months.
UNASSIGNED: This prospective study highlights mifepristone\'s promise as a non-surgical approach to effectively reduce uterine fibroid volume, improve hemoglobin levels, and mitigate uterine blood loss in patients.
■前瞻性地进行,这项研究招募了20名绝经前妇女,18岁或以上,孟买纳纳瓦蒂·马克斯超级专科医院,马哈拉施特拉邦,印度。参与者是根据具体的入选标准选择的,包括超声证实的至少一个最小直径为2.5厘米的子宫肌瘤的存在。参与者的平均年龄为39.75岁,平均BMI为27.58kg/m2。
■研究发现米非司酮使子宫体积显著减少75%,血红蛋白水平从最初的9gm/dL大幅改善至6个月后的12.51gm/dL。疼痛强度,使用视觉模拟量表(VAS)评分进行评估,从基线逐渐下降到三个月,所有20例患者报告到6个月时完全没有盆腔疼痛。
这项前瞻性研究强调了米非司酮作为有效减少子宫肌瘤体积的非手术方法的承诺,提高血红蛋白水平,减轻患者的子宫失血。